Vaccines

NewcelX sharpens its focus on a Type 1 Diabetes cell therapy, but faces a competitive landscape and significant financial hurdles in its ambitious quest.

A German biotech's novel oral drug for herpes is moving to Phase 2 trials, offering new hope against a widespread and often resistant virus.

Over 60% of cats and 59% of dogs are overweight, a silent crisis shortening lives. Vets warn against risky shortcuts and urge proactive, guided care.

As drug-resistant fungi pose a grave threat, SCYNEXIS presents promising data on SCY-247, a next-gen drug that could redefine the fight against infection.

With promising brain scan data, a deep therapeutic pipeline, and a cash runway into 2027, Radiopharm Theranostics is gaining significant momentum.

A new study reveals albumin, the most abundant protein in blood, is a powerful weapon against mucormycosis, offering new hope for treating this fatal infection.

A new COVID-19 drug targets patients who can't take Paxlovid, while a once-a-month pill could revolutionize how we prevent seasonal influenza.

A major clinical trial setback for a promising liver disease drug leaves patients waiting and puts Bausch Health's future strategy under scrutiny.

Swiss biotech GeNeuro suspends trading, awaiting a critical court ruling on its debt moratorium that will decide its fate and the future of its novel drugs.

Swedish biotech innovator Hansa Biopharma wins a top award for its life-saving transplant tech, facing a pivotal year with FDA review on the horizon.

With demand soaring, diagnostics leader PreludeDx hires veteran MiMi Reyes to scale lab operations and spearhead the launch of its new AidaBreast test.

An investigational drug from Veloxis Pharmaceuticals has received a key FDA designation, offering new hope for liver transplant patients facing lifelong toxic therapies.

BioAge Labs is developing an oral drug for diabetic macular edema, a breakthrough that could end the need for frequent, invasive eye injections for millions.

GSK's subsidiary Tesaro inks a deal worth up to $285M with Alteogen to create an under-the-skin version of its cancer drug Jemperli.

Amid a concerning rise in cervical cancer rates, a new initiative is bringing vital screenings directly to communities where they are needed most.

From developing neonatal ventilators to pivotal COVID vaccine research, a San Antonio institute marks 85 years on the front lines of global health.

Eagle Pharmaceuticals divests its unique post-op nausea drug to France's LXO Group, signaling a strategic pivot to oncology and critical care.

The biopharma firm projects massive sales from its current drugs and bets big on a new Alzheimer's therapy, signaling a pivotal year of growth and innovation.

Pimicotinib, a once-daily pill for tenosynovial giant cell tumor, gains FDA review, offering new hope for patients beyond invasive surgery.

Following a successful three-year transformation, B-FLEXION acquires full ownership of Radius Health, betting big on its blockbuster osteoporosis drug TYMLOS®.